Star Equity Holdings, Inc. (STRR)
USD 1.83
(-3.12%)
USD 1.83
(-3.12%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 45.78 Million USD | -59.18% |
| 2022 | 112.15 Million USD | 5.25% |
| 2021 | 106.55 Million USD | 36.33% |
| 2020 | 78.16 Million USD | -31.55% |
| 2019 | 114.18 Million USD | 9.6% |
| 2018 | 104.18 Million USD | -11.96% |
| 2017 | 118.33 Million USD | -5.68% |
| 2016 | 125.46 Million USD | 106.27% |
| 2015 | 60.82 Million USD | 9.38% |
| 2014 | 55.6 Million USD | 12.62% |
| 2013 | 49.37 Million USD | -2.25% |
| 2012 | 50.51 Million USD | -6.01% |
| 2011 | 53.74 Million USD | -4.34% |
| 2010 | 56.18 Million USD | -19.27% |
| 2009 | 69.59 Million USD | -13.39% |
| 2008 | 80.35 Million USD | 8.67% |
| 2007 | 73.94 Million USD | 2.81% |
| 2006 | 71.92 Million USD | 5.48% |
| 2005 | 68.18 Million USD | 0.07% |
| 2004 | 68.13 Million USD | 21.16% |
| 2003 | 56.23 Million USD | 35.41% |
| 2002 | 41.53 Million USD | 46.73% |
| 2001 | 28.3 Million USD | 300.06% |
| 2000 | 7.07 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 9.11 Million USD | -35.38% |
| 2024 Q2 | 13.48 Million USD | 47.87% |
| 2023 Q4 | 14.11 Million USD | 35.23% |
| 2023 Q3 | 10.43 Million USD | 17.34% |
| 2023 FY | 45.78 Million USD | -59.18% |
| 2023 Q1 | 25.7 Million USD | -20.02% |
| 2023 Q2 | 8.89 Million USD | -65.4% |
| 2022 FY | 112.15 Million USD | 5.25% |
| 2022 Q1 | 25.04 Million USD | -15.2% |
| 2022 Q2 | 16.8 Million USD | -32.91% |
| 2022 Q3 | 24.24 Million USD | 44.26% |
| 2022 Q4 | 32.14 Million USD | 32.57% |
| 2021 Q3 | 28.85 Million USD | 11.83% |
| 2021 Q2 | 25.8 Million USD | 15.44% |
| 2021 FY | 106.55 Million USD | 36.33% |
| 2021 Q1 | 22.35 Million USD | -3.41% |
| 2021 Q4 | 29.54 Million USD | 2.36% |
| 2020 FY | 78.16 Million USD | -31.55% |
| 2020 Q2 | 22.34 Million USD | -22.58% |
| 2020 Q3 | 30.35 Million USD | 35.86% |
| 2020 Q4 | 23.14 Million USD | -23.75% |
| 2020 Q1 | 28.85 Million USD | -20.16% |
| 2019 FY | 114.18 Million USD | 9.6% |
| 2019 Q4 | 36.14 Million USD | 27.56% |
| 2019 Q1 | 23.91 Million USD | -7.78% |
| 2019 Q2 | 25.79 Million USD | 7.89% |
| 2019 Q3 | 28.33 Million USD | 9.83% |
| 2018 Q4 | 25.92 Million USD | 0.86% |
| 2018 Q3 | 25.7 Million USD | -5.07% |
| 2018 FY | 104.18 Million USD | -11.96% |
| 2018 Q1 | 25.46 Million USD | -17.64% |
| 2018 Q2 | 27.08 Million USD | 6.34% |
| 2017 Q1 | 29.08 Million USD | -6.6% |
| 2017 FY | 118.33 Million USD | -5.68% |
| 2017 Q4 | 30.91 Million USD | 8.28% |
| 2017 Q3 | 28.55 Million USD | -4.13% |
| 2017 Q2 | 29.78 Million USD | 2.43% |
| 2016 Q1 | 31.15 Million USD | 100.01% |
| 2016 Q4 | 31.13 Million USD | 0.15% |
| 2016 Q3 | 31.08 Million USD | -3.13% |
| 2016 FY | 125.46 Million USD | 106.27% |
| 2016 Q2 | 32.09 Million USD | 2.99% |
| 2015 Q2 | 15.54 Million USD | 12.34% |
| 2015 FY | 60.82 Million USD | 9.38% |
| 2015 Q4 | 15.57 Million USD | -1.79% |
| 2015 Q1 | 13.83 Million USD | -2.15% |
| 2015 Q3 | 15.86 Million USD | 2.03% |
| 2014 Q1 | 12.99 Million USD | 3.75% |
| 2014 Q2 | 14.58 Million USD | 12.23% |
| 2014 FY | 55.6 Million USD | 12.62% |
| 2014 Q4 | 14.14 Million USD | 1.89% |
| 2014 Q3 | 13.88 Million USD | -4.84% |
| 2013 Q2 | 12.89 Million USD | 11.64% |
| 2013 FY | 49.37 Million USD | -2.25% |
| 2013 Q4 | 12.52 Million USD | 0.92% |
| 2013 Q3 | 12.41 Million USD | -3.7% |
| 2013 Q1 | 11.54 Million USD | -11.29% |
| 2012 FY | 50.51 Million USD | -6.01% |
| 2012 Q3 | 11.81 Million USD | -7.03% |
| 2012 Q2 | 12.71 Million USD | -2.0% |
| 2012 Q1 | 12.96 Million USD | 9.15% |
| 2012 Q4 | 13.01 Million USD | 10.15% |
| 2011 Q1 | 14.17 Million USD | -3.29% |
| 2011 FY | 53.74 Million USD | -4.34% |
| 2011 Q4 | 11.88 Million USD | -11.59% |
| 2011 Q3 | 13.43 Million USD | -5.68% |
| 2011 Q2 | 14.24 Million USD | 0.52% |
| 2010 FY | 56.18 Million USD | -19.27% |
| 2010 Q1 | 15.06 Million USD | -8.11% |
| 2010 Q4 | 14.65 Million USD | 10.21% |
| 2010 Q3 | 13.29 Million USD | 1.06% |
| 2010 Q2 | 13.15 Million USD | -12.68% |
| 2009 FY | 69.59 Million USD | -13.39% |
| 2009 Q2 | 18.55 Million USD | 4.79% |
| 2009 Q3 | 16.92 Million USD | -8.79% |
| 2009 Q1 | 17.71 Million USD | -19.45% |
| 2009 Q4 | 16.39 Million USD | -3.13% |
| 2008 Q1 | 18.27 Million USD | -2.93% |
| 2008 Q2 | 19.89 Million USD | 8.9% |
| 2008 Q3 | 20.2 Million USD | 1.54% |
| 2008 Q4 | 21.98 Million USD | 8.83% |
| 2008 FY | 80.35 Million USD | 8.67% |
| 2007 Q4 | 18.82 Million USD | 0.26% |
| 2007 Q1 | 17.53 Million USD | 1.69% |
| 2007 Q2 | 18.81 Million USD | 7.26% |
| 2007 FY | 73.94 Million USD | 2.81% |
| 2007 Q3 | 18.77 Million USD | -0.2% |
| 2006 Q2 | 19.02 Million USD | 0.35% |
| 2006 Q3 | 16.7 Million USD | -12.2% |
| 2006 FY | 71.92 Million USD | 5.48% |
| 2006 Q1 | 18.95 Million USD | 8.92% |
| 2006 Q4 | 17.24 Million USD | 3.26% |
| 2005 Q3 | 17.35 Million USD | 12.22% |
| 2005 Q4 | 17.4 Million USD | 0.29% |
| 2005 FY | 68.18 Million USD | 0.07% |
| 2005 Q1 | 17.97 Million USD | 1.21% |
| 2005 Q2 | 15.46 Million USD | -13.96% |
| 2004 Q4 | 17.75 Million USD | 3.08% |
| 2004 Q2 | 17.29 Million USD | 8.96% |
| 2004 FY | 68.13 Million USD | 21.16% |
| 2004 Q3 | 17.22 Million USD | -0.38% |
| 2004 Q1 | 15.86 Million USD | 0.0% |
| 2003 Q2 | 14.01 Million USD | 7.96% |
| 2003 Q1 | 12.97 Million USD | 0.0% |
| 2003 FY | 56.23 Million USD | 35.41% |
| 2002 FY | 41.53 Million USD | 46.73% |
| 2001 FY | 28.3 Million USD | 300.06% |
| 2000 FY | 7.07 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -46.517% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | -242.511% |
| Aspira Women's Health Inc. | 9.15 Million USD | -400.164% |
| Biodesix, Inc. | 49.08 Million USD | 6.727% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -368.59% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -1707.898% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -1707.898% |
| Bionano Genomics, Inc. | 36.11 Million USD | -26.772% |
| CareDx, Inc | 280.32 Million USD | 83.667% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 219.78 Million USD | 79.169% |
| DarioHealth Corp. | 20.35 Million USD | -124.966% |
| Exact Sciences Corporation | 2.49 Billion USD | 98.168% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 84.169% |
| Guardant Health, Inc. | 563.94 Million USD | 91.881% |
| ICON Public Limited Company | 8.12 Billion USD | 99.436% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 98.749% |
| Illumina, Inc. | 4.5 Billion USD | 98.983% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -1371.344% |
| iSpecimen Inc. | 9.92 Million USD | -361.162% |
| Standard BioTools Inc. | 106.34 Million USD | 56.945% |
| MDxHealth SA | 70.19 Million USD | 34.773% |
| 23andMe Holding Co. | 219.63 Million USD | 79.154% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 97.572% |
| Myriad Genetics, Inc. | 678.4 Million USD | 93.251% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -5012.906% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| NeoGenomics, Inc. | 591.64 Million USD | 92.261% |
| Neogen Corporation | 924.22 Million USD | 95.046% |
| Inotiv, Inc. | 572.42 Million USD | 92.002% |
| Natera, Inc. | 1.08 Billion USD | 95.771% |
| OpGen, Inc. | 3.41 Million USD | -1239.401% |
| OPKO Health, Inc. | 863.49 Million USD | 94.698% |
| Psychemedics Corporation | 22.09 Million USD | -107.191% |
| Prenetics Global Limited | 21.74 Million USD | -110.577% |
| Prenetics Global Limited | 21.74 Million USD | -110.577% |
| Precipio, Inc. | 15.19 Million USD | -201.277% |
| Personalis, Inc. | 73.48 Million USD | 37.691% |
| RadNet, Inc. | 1.61 Billion USD | 97.168% |
| Sera Prognostics, Inc. | 306 Thousand USD | -14862.418% |
| Sotera Health Company | 1.04 Billion USD | 95.637% |
| Neuronetics, Inc. | 71.34 Million USD | 35.829% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 0.0% |
| Trinity Biotech plc | 56.83 Million USD | 19.438% |
| T2 Biosystems, Inc. | 7.19 Million USD | -536.522% |
| Twist Bioscience Corporation | 312.97 Million USD | 85.371% |
| Exagen Inc. | 52.54 Million USD | 12.87% |